September 19th, 2014

Call to Protect Public Health by Bolstering the World’s Defense Against Antimicrobial Resistance

by Adrian Thomas M.D., Vice President, Global Market Access & Commercial Strategy Operations and Head, Global Public Health at Janssen

Early in my career in Australia’s Flying Doctor Service, I had the privilege of providing emergency care to the rural poor.  In many cases, I was able to give my patients innovative treatments that cured their ailments and improved their health and lives overall.  The feelings I experienced from helping those vulnerable patients stays with me today and continues to drive me in my current role overseeing our global health portfolio of products and services for diseases of high public health impact and working with committed leaders advancing our technologies including those directed against HIV, tuberculosis, and Ebola.

Providing patients with effective treatments is the goal of every healthcare professional, scientific researcher, developer and manufacturer of new treatments and therapies.  When those treatments and therapies don’t exist, there is nothing harder than looking into the eyes of your patient and their loved ones and telling them there are no options.  It is their stories that compel us to do more to meet their needs by working together to bring forward new therapies.

The recent Ebola crisis and the rise in drug-resistant bacteria have forced our attention to the inadequacy of our therapeutic arsenals to address these major public health threats. 

Read More

September 12th, 2014

Transforming the Global Tuberculosis Response: Putting an End to Pediatric TB

by Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Janssen

In today’s global health efforts, we continuously highlight the plight of disease on children and remind ourselves that the needs of this population cannot be forgotten. In some areas, we have done extremely well in ensuring that young people receive the care they need to live healthy lives. For example, there has been a recent groundswell of activity around pediatric HIV, with growing awareness leading to unprecedented financial and resource commitments directed towards this important issue.

In other areas, however, we, as a global health community, have been less successful at mobilizing global support. Childhood tuberculosis (TB), in particular, is a serious problem that has received inadequate attention in international discussions. While TB more generally has garnered greater investment in recent years (due in large part to the creation of organizations like the Global Fund to Fight AIDS, Tuberculosis and Malaria), the specific needs of children suffering from the disease have been largely neglected. The first-ever targeted roadmap to end childhood TB deaths was only published less than a year ago.

In large part, this is because we simply didn’t know the magnitude of the problem. The results of a recent study conducted by Harvard Medical School revealed that one million children suffer from TB each year – twice the number previously thought to have TB and three times the number of children that are diagnosed.

Read More

September 8th, 2014

World Suicide Prevention Day

By Dr. Husseini Manji and Dr. Carla Canuso

Tragically, approximately one million people die from suicide each year worldwide.  While the act of taking one’s life may be unthinkable to most people, suicide is among the top 10 causes of death in most countries and accounts for more lives lost each year than homicide and war combined.  It is a complex phenomenon influenced by biological, psychological, socio-cultural, and environmental factors.

Brain disorders, particularly depression and alcohol/substance use disorders, are a major risk factor for suicide.  Indeed, nearly two-thirds of people who commit suicide are depressed at the time of their deaths.  Other important risk factors include being male, having a family history of suicide, and suffering from a chronic medical condition.

Our heightened awareness of depression and its ravages is leading to increasingly widespread recognition that brain disorders are, all too often, fatal illnesses. This recognition is a key first step in suicide prevention.

It’s very important to understand that depression and substance abuse are treatable conditions, and there is help and hope for people who are suffering. The first step is to reach out for help to  a friend, family member, physician,  or other health care professional.  For more information about depression, see the Janssen Healthy Minds video here.

Read More

September 5th, 2014

Racing For A Cause

Editor’s Note: September is AFib Awareness Month. In this post, NASCAR® Legend Michael Waltrip opens up about his mother’s experience with atrial fibrillation and stroke. During the month Michael is teaming up with Janssen, a Johnson & Johnson company, to help raise awareness about this condition.

By Michael Waltrip, NASCAR® Team Owner and Driver

As a racecar driver, I’ve had my fair share of hits, twists and turns. But one of the hardest hits I ever took was when my mom had a major stroke due to atrial fibrillation, or AFib, which left her permanently disabled. This was the moment that tables turned—our family knew we were all going to have to pitch in and care for her the same way she has cared for us all of our lives.

I recall 25 years ago my mom having a heart condition, which was an irregular heartbeat called Atrial Fibrillation or AFib. Now, I know that AFib is the most common “serious” abnormal heart rhythm in people over 65. What I wasn’t aware of is what AFib could do to my mother. None of us had any idea that she was at an increased risk of stroke because of it. 

Read More

September 4th, 2014

Helping to Tackle the Ebola Outbreak

By Alex Gorsky, Chairman and CEO of Johnson & Johnson

As the Ebola outbreak in West Africa continues to spread, we are reminded of our critical responsibility as the world’s largest health care company to help improve the lives of people around the globe whether it is working to prevent diseases in vulnerable populations or contributing to humanitarian relief efforts.

During this crucial time as the Ebola virus threatens to infect thousands more, we are working diligently to broadly collaborate with global health organizations and government agencies in the region to help minimize the impact of this crisis. Specifically, we are contributing to relief efforts to provide immediate aid to those people and health workers at the center of this tragedy, and are accelerating our efforts to advance our own Ebola vaccine research program.

With support from the U.S. National Institutes of Health (NIH), we plan to work with Bavarian Nordic on a combination vaccine to target the Zaire strain of the Ebola filovirus responsible for the current outbreak. If we are successful, we expect this preventive vaccine to play an invaluable role in helping to protect people from contracting the Ebola virus and ultimately save lives.

The more immediate measures we have underway to support relief efforts include financial support of the non-profit organization Direct Relief International to facilitate the air transport of a variety of infection prevention products en route to Monrovia.

Read More

August 13th, 2014

Janssen Healthy Minds Program Explores Major Depressive Disorder

BrainHealthPost

As there is significant public discussion right now about depression, Janssen Research & Development, LLC, a Johnson & Johnson Company, is posting its Healthy Minds segment about major depressive disorder ahead of its planned release in October to help provide some additional resources on this disorder. Major depression, a largely misunderstood disease, is expected to be the number one cause of disability worldwide by 2030, and tragically there are more than 38,000 suicides in the United States each year.

Featured in the video series is Dr. Husseini Manji, a psychiatrist and neuroscientist, and Global Therapeutic Area Head for Neuroscience at Janssen R&D. The Healthy Minds video series is hosted by Emmy Award-winning broadcast journalist Vicki Mabrey.

Across the globe, approximately 450 million people suffer from a mental or neurological disorder, yet nearly 60 percent who have a known disorder never consult a doctor to better understand their mental health. Lack of awareness and stigma are frequently noted as the reasons those suffering do not seek help. The video series aims to assist in familiarizing these disorders with viewers and reducing the stigma associated with them.

The first video, A Discussion about Brain Health, is available on the Johnson & Johnson YouTube channel and the J&J Corporate Blog.

Read More

August 4th, 2014

Education about Brain Disorders Benefits Us All

By Vicki Mabrey, Guest Contributor to JNJ Blog

Editor’s Note: Emmy-award winning journalist Vicki Mabrey is the host of Healthy Minds, a new digital news program about brain health from Janssen Research & Development, LLC, a Johnson & Johnson Company. 

BrainHealthPost

Recently, it was my pleasure to learn more about the brain and disorders of the brain when I interviewed Janssen’s Global Therapeutic Area Head for Neuroscience, Dr. Husseini Manji. Dr. Manji shared his knowledge with me for the new Healthy Minds video series, which is launching this week on the Johnson & Johnson You Tube channel. It will cover general brain health, bipolar disorder, major depressive disorder, Alzheimer’s disease and schizophrenia. Working on the Healthy Minds series helped me to better understand the complexities of the brain and gain insights into diseases we hear about every day because our mothers, fathers, sons, daughters, and neighbors are suffering from them.

BrainHealth2

Throughout the world, about 450 million people suffer from a brain disorder, and in the US about one in four adults suffer from a diagnosable mental illness. That calculates to almost 60 million people.  Despite the prevalence and impact of these illnesses, nearly 60 percent of those affected do not consult medical professionals for treatment.

Read More

August 4th, 2014

The Johnson & Johnson Official 7 Minute Workout Station Debuts in Biddeford, Maine

By Chris Jordan, Director of Exercise Physiology, Human Performance Institute Division of Wellness & Prevention, Inc., a Johnson & Johnson company 

7Minuteworkout0804This summer the City of Biddeford, Maine, working with Johnson & Johnson, launched a 7 Minute Workout Station, providing the local community and visitors the opportunity to get a simple, fast, science-based workout for free. The station is a freestanding structure that is modeled after the Johnson & Johnson Official 7 Minute Workout, and includes instructions on how to execute each exercise using the station. It was an exciting day for me – a high point that’s been many years in the making.

As an exercise physiologist for almost 20 years, I am passionate about promoting physical activity and making it accessible to everyone.  Several years ago, as part of my role as Director of Exercise Physiology with the Human Performance Institute, I created a simple, fast, and effective workout that requires nothing more than a floor, a wall, and a chair, and can be done by almost anyone, anywhere, anytime.

The workout comprises a circuit of 12 bodyweight exercises, each performed for 30 seconds with minimal rest between exercises. One circuit, therefore, takes approximately 7 minutes.

In May 2013, my co-authored article providing the science behind this workout was published in the peer-reviewed American College of Sports Medicine’s Health & Fitness Journal.

Read More

August 1st, 2014

Our Path to 60: A Journey of Product Stewardship at Johnson & Johnson

by Brian K. Boyd, Vice President, Environment, Health, Safety & Sustainability, Johnson & Johnson

Earthwards Path to 60

A core tenet of Johnson & Johnson’s citizenship and sustainability commitments is our focus on safeguarding the planet. As my colleague Shaun Mickus recently discussed, our company has been guided by Our Credo since 1943, which is when the notion of sustainability got its formal start at Johnson & Johnson. Environmental responsibility is as important to us today as it was back then.

As head of environment, health, safety and sustainability at Johnson & Johnson, I’m accountable for ensuring our operations and products live up to the promise explicitly expressed in Our Credo: We must maintain in good order the property we are privileged to use, protecting the environment and natural resources. This has been a powerful motivator for the people at Johnson & Johnson to focus on improving the footprints of our products, primarily by reducing the environmental impacts associated with their lifecycle.

In 2009, we developed and launched Earthwards®, which has subsequently become Johnson & Johnson’s companywide approach to product stewardship and sustainability. Today, the Earthwards® approach empowers our product teams to work together on identifying the most significant environmental impacts of individual products, continually innovate better solutions to address these impacts, and ultimately create more sustainable products for our customers.

Read More

July 28th, 2014

World Hepatitis Day — Why We Should All Think Again

HepatitisBlog0728

By Kris Sterkens, Company Group Chairman, Janssen, the pharmaceutical companies of Johnson & Johnson, Asia Pacific

Today is World Hepatitis Day, one of only four disease-related awareness days officially endorsed by the World Health Organization (WHO).  This year’s theme is ‘Think Again’, calling upon policy-makers, health workers and the public to re-think viral hepatitis.

It’s a critically important day because more than 500 million people, many unknowingly, are affected by viral hepatitis globally. And more so for us here in Asia Pacific where recent data showed that 70% of the 1.4 million annual global deaths associated with the disease occur.

It’s why the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) launched the ‘One Million Lives Lost’ social media campaign last year – drawing attention to the fact that every 30 seconds, one person dies from these devastating diseases in Asia Pacific countries.

Driven by our commitment to patients, we have developed some of the first new medicines for hepatitis C in nearly a decade. These are today positively impacting thousands of patients affected by hepatitis C.  But we don’t stop there.  We want to further transform how viral hepatitis is treated.  This is why we maintain a strong and robust research program in both hepatitis B and C.

Read More